Literature DB >> 670832

Isolation and characterization of human liver hematoside.

T N Seyfried, S Ando, R K Yu.   

Abstract

The monosialoganglioside hematoside (GM3) is an important precursor in the synthesis of the more complex gangliosides. To obtain large quantities of GM3 for use in ganglioside biosynthetic experiments, we have devised a column chromatographic procedure for the isolation and purification of GM3 from human liver. A total ganglioside mixture was obtained from a 550 g sample of normal human liver. Quantitative analysis by gas-liquid chromatography indicated about 66 microgram of lipid-bound N-acetylneuraminic acid per gram of fresh tissue. Hematoside appeared as double bands on thin-layer plates and represented 86.4% of the total sialic acid content. Additional ganglioside species, notably GD3, were also seen. Hematoside was separated from the other gangliosides by GM3 obtained was 120 mg, which represented a 90% recovery. Although the long-chain base and sugar compositions of the upper and lower GM3 fractions were similar, striking fatty acid differences were detected. The upper fraction contained predominantly unsubstituted fatty acids, while the lower fraction showed a preponderance of alpha-hydroxy fatty acids. The unsubstituted fatty acid and hydroxy fatty acid composition of the total GM3 fraction was calculated to be 56.9% and 43.1%, respectively.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 670832

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  21 in total

Review 1.  Fatty acid 2-Hydroxylation in mammalian sphingolipid biology.

Authors:  Hiroko Hama
Journal:  Biochim Biophys Acta       Date:  2009-12-21

2.  Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.

Authors:  J R Arthur; J P Lee; E Y Snyder; T N Seyfried
Journal:  Neurochem Res       Date:  2012-02-25       Impact factor: 3.996

3.  Establishment of a monoclonal antibody directed against Gb3Cer/CD77: a useful immunochemical reagent for a differentiation marker in Burkitt's lymphoma and germinal centre B cells.

Authors:  D Miyamoto; T Ueno; S Takashima; K Ohta; T Miyawaki; T Suzuki; Y Suzuki
Journal:  Glycoconj J       Date:  1997-04       Impact factor: 2.916

4.  Sialidase of swine influenza A viruses: variation of the recognition specificities for sialyl linkages and for the molecular species of sialic acid with the year of isolation.

Authors:  G Xu; T Suzuki; Y Maejima; T Mizoguchi; M Tsuchiya; M Kiso; A Hasegawa; Y Suzuki
Journal:  Glycoconj J       Date:  1995-04       Impact factor: 2.916

5.  Synthetic sialylphosphatidylethanolamine derivatives bind to human influenza A viruses and inhibit viral infection.

Authors:  C T Guo; C H Wong; T Kajimoto; T Miura; Y Ida; L R Juneja; M J Kim; H Masuda; T Suzuki; Y Suzuki
Journal:  Glycoconj J       Date:  1998-11       Impact factor: 2.916

6.  Gangliosides in membranes from Torpedo electric organ.

Authors:  R M Hann; J E Evans; R H McCluer; V A Eterovic
Journal:  Lipids       Date:  1996-06       Impact factor: 1.880

7.  Single-amino-acid substitution in an antigenic site of influenza virus hemagglutinin can alter the specificity of binding to cell membrane-associated gangliosides.

Authors:  Y Suzuki; H Kato; C W Naeve; R G Webster
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  Differences in liver ganglioside patterns in various inbred strains of mice.

Authors:  R Ghidoni; S Sonnino; V Chigorno; B Venerando; G Tettamanti
Journal:  Biochem J       Date:  1983-03-01       Impact factor: 3.857

9.  Cryoprecipitation of an anti-Pr2 monoclonal IgM cold agglutinin in the presence of GM3 ganglioside.

Authors:  P Yeni; M L Harpin; B Habibi; A Billecocq; M J Morelec; J P Clauvel; F Danon; N Baumann; J C Brouet
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

10.  Ganglioside GM2 as a human tumor antigen (OFA-I-1).

Authors:  T Tai; J C Paulson; L D Cahan; R F Irie
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.